Revenue segments as reported by the company.

Diabetes

Oncology

Immunology

Neuroscience

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Marketing, selling and administrative

Acquired in-process research and development

Asset impairment, restructuring and other special charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Eli Lilly

Cialis, ia a competitor to Pfizer's blockbuster Viagra for erectile dysfunction. Cialis maintains an active period of 36 hours.

Cialis

Cymbalta is a serotonin-norepinephrine reuptake inhibitor used predominantly in the treatment of major depressive disorders and generalized anxiety disorder, ranks with Prozac as one of the most financially successful pharmaceuticals in industry history. It is also used in the treatment of fibromyalgia, neuropathy, chronic pain and osteoarthritis.

Cymbalta

Gemzar is a treatment of pancreatic cancer. Gemzar is commonly used in the treatment of pancreatic cancer, usually in coordination with 5-FU chemotherapy and radiology. Gemzar also is routinely used in the treatment of non-small cell lung cancer.

Gemzar

Methadone is an analgesic used frequently in the treatment of heroin, opium and other opioid and narcotic drug addictions.

Methadone

Prozac was one of the first therapies in its class to treat clinical depression by blocking the uptake of serotonin within the human brain. It is prescribed to more than fifty-four million people worldwide.

Prozac

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Eli Lilly reports robust Q4 earnings, eyes growth in innovative therapies

Eli Lilly's Q4 2022 earnings call highlighted strong financial performance, pipeline advancements, and strategic initiatives for future growth.
The company's focus on innovation, FDA approvals, and market expansion underscores its commitment to addressing unmet medical needs and driving shareholder value.
Challenges in physician education, obesity treatment development, and market access present areas for strategic focus and investment for sustained growth.
Opportunities in expanding manufacturing capacity, engaging with payers, and capitalizing on consumer interest in obesity treatments position Lilly for continued success in 2023.

Eli Lilly reports robust Q1 growth amidst capacity challenges

Eli Lilly's Q1 2023 performance reflects strong revenue growth and strategic investments in new products and facilities.
While facing challenges in capacity and supply pressure, the company's focus on pipeline advancements and market opportunities positions it for future growth.
Opportunities in international markets, cardiovascular trials, and product promotion present avenues for continued expansion and revenue growth.
Overall, Eli Lilly's financial performance, product strengths, and strategic initiatives demonstrate a resilient and growth-focused approach.

Eli Lilly reports robust Q2 earnings, eyes growth through innovation

Eli Lilly's Q2 earnings call showcased strong financial performance, revenue growth, and advancements in its pipeline, driven by key products and strategic investments.
The company faces challenges in managing increased expenses, supply chain constraints, and regulatory considerations, requiring strategic decision-making and operational agility.
Opportunities lie in expanding market access, leveraging innovative treatments like tirzepatide, and enhancing manufacturing capabilities to drive future growth and competitive advantage.
Overall, Lilly's focus on innovation, market expansion, and addressing health needs positions it well for sustained growth and leadership in the pharmaceutical industry.

Eli Lilly posts robust Q3 results, eyes expansion and commercial growth

Eli Lilly (LLY) showcased strong financial performance and pipeline advancements in Q3 2023.
Challenges include supply restrictions and pricing decisions, but opportunities lie in expansion plans and commercial coverage ramp-up.
Investors advised to focus on guidance range for insights into 2024 expectations.

Eli Lilly posts robust Q4 results, eyes global expansion opportunities

Eli Lilly's strong financial performance in Q4 2023, driven by revenue growth and operational efficiency, sets a solid foundation for future growth.
The company's strategic acquisitions, global expansion plans, and focus on innovation position it well for continued success and market leadership.
Challenges in drug development and manufacturing require careful navigation, but opportunities in new drug trials and market expansion offer avenues for growth.
Overall, Eli Lilly's 2023 was marked by productivity and anticipation of sustained momentum in 2024, reflecting a positive outlook for the company.

Eli Lilly reports robust Q1 growth, eyes pipeline opportunities

Eli Lilly's Q1 performance showcased strong revenue growth, driven by new products and global market expansion.
While facing challenges like low Zepbound volume and manufacturing complexities, Lilly's strengths in innovation and market presence position it well for growth.
Opportunities in pipeline advancements, differentiation in drug portfolios, and potential Alzheimer's treatments signal a promising future for the company.
Overall, Eli Lilly's strategic focus on growth, innovation, and market expansion sets a positive trajectory for continued success.

Eli Lilly reports stellar Q3 results, eyes global expansion opportunities

Eli Lilly's Q3 performance reflects robust revenue growth, driven by new products and strategic investments, positioning the company for continued success.
Key pipeline advancements and revenue guidance raise optimism for future growth, with a focus on global scaling and market expansion initiatives.
Challenges in patient adherence and treatment efficacy are being addressed, while opportunities in market penetration and revenue growth are actively pursued.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Glucagon-like peptide-1 (GLP-1) agonists such as Mounjaro and Zepbound have been multibillion-dollar hits for Lilly, and their growth could just be getting started. Lilly is about to enter the Alzheimer's market, an opportunity worth more than $30 billion where it has little in the way of competition.

This Unstoppable Stock Has Gained 100,203% Over The Last 50 Years, Creating Many Millionaires in the Process. Here Are 3 Reasons I Think It Will Continue to Create Generational Wealth.

Eli Lilly has three likely blockbuster drugs that are relatively new to the market. Its pipeline features three other late-stage candidates with blockbuster potential.

Beyond Mounjaro and Zepbound: 6 Other Drugs That Could Be Blockbusters for Eli Lilly

MercadoLibre

Microsoft

Unless you have been living under the rock, you'd have heard of Nvidia's (NASDAQ: NVDA) success story.

Prediction: These 3 Stocks Will Outperform NVIDIA in 2025

argenx

Rhythm Pharmaceuticals

TG Therapeutics

Biotech stocks have been rallying as funds load up. Five stocks have been outperforming the vast majority in the IBD database.

Four Biotech Stocks Rally Toward Buy Points As Funds Load Up

Data from two late-stage studies show that LLY's once-weekly insulin injections achieved results that are similar to daily insulin shots.

Eli Lilly's Weekly Insulin Shot Meets Two Late-Stage Study Goals

When stocks rally, they tend to run into resistance if they reach a price level that had been resistance before. And sometimes, after hitting it they reverse and head lower.

Stock Of The Day: Here's Why Weight-Loss Drug Maker Eli Lilly Has Reversed

Eli Lilly's experimental next generation weight-loss drug mimics three hormones instead of just one or two and continues to show promising clinical trial results for additional health benefits, the company said.

Health Rounds: Next generation Lilly weight-loss drug shows added heart, liver benefits

Eli Lilly's weight loss drugs are bringing in billions of dollars in revenue, and their performance even prompted the company to increase its annual revenue guidance. But one thing has limited the revenue potential of these drugs.

This Big Move by Eli Lilly May Solve the Weight Loss Drug Market's Biggest Problem

Eli Lilly could be on its way to topping $1 trillion in market value. Meanwhile, Abbott launches its first over-the-counter continuous glucose monitor in U.S.

Healthy Returns: Eli Lilly could soon become the first $1 trillion health-care stock

Eli Lilly and Company (NYSE:LLY ) Morgan Stanley 22nd Annual Global Healthcare Conference Call September 5, 2024 7:45 AM ET Company Participants Jacob Van Naarden - Executive Vice President & President of Lilly Oncology Conference Call Participants Terence Flynn - Morgan Stanley Terence Flynn All right. Good morning, everybody.

Eli Lilly and Company (LLY) Morgan Stanley 22nd Annual Global Healthcare Conference (Transcript)

Eli Lilly has entered into a research deal with artificial intelligence-focused firm Genetic Leap for up to $409 million to develop genetic medicines, the latter said on Thursday.

Eli Lilly signs research deal with AI-focused Genetic Leap

Novo Nordisk

A pair of late-stage trials found that Eli Lilly's experimental once-weekly insulin can lower blood sugar as effectively as widely used daily insulins, the drugmaker said Thursday, intensifying the company's race with Novo Nordisk to develop longer-acting insulins.

Eli Lilly's weekly insulin intensifies race with Novo Nordisk

As demand soars for weight loss medications, so has the competition. Eli Lilly slashed prices for its hugely successful obesity medication, Zepbound.

Eli Lilly Just Made Zepbound Even More Appealing. Here's What Smart Investors Need to Know.

In the phase 3 study, QWINT-1, efsitora was administered via four fixed doses once weekly in a single-use autoinjector in people with type 2 diabetes using basal insulin for the first time In a second phase 3 study, QWINT-3, efsitora also delivered non-inferior A1C reduction compared to daily insulin in people with type 2 diabetes switching from daily basal injections INDIANAPOLIS , Sept. 5, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the QWINT-1 and QWINT-3 phase 3 clinical trials evaluating once weekly insulin efsitora alfa (efsitora) in adults with type 2 diabetes using basal insulin for the first time (insulin naïve) and in those who have switched from daily basal insulin injections, respectively.

In a first-of-its-kind fixed dose study, once weekly insulin efsitora alfa leads to A1C reduction similar to daily insulin

Does Eli Lilly (LLY) have what it takes to be a top stock pick for momentum investors? Let's find out.

Eli Lilly (LLY) is a Great Momentum Stock: Should You Buy?

Weight-loss drug kingpins Eli Lilly and Novo Nordisk could join the trillion-dollar company club before even Tesla, according to a report.

How Lilly, Novo Could Beat Tesla To The Trillion-Dollar Club; Plus, Nvidia's Battle With Microsoft, Apple

Power Inflow occurred at 10:31 am at 958.10. The stock rose to 965.94 at 11:37 am.

Trade Pulse Power Inflow Alert: Eli Lilly Stock Rises Over 7 Points

LAUSANNE, Switzerland & SAN DIEGO--(BUSINESS WIRE)---- $LLY #HAYA--HAYA Therapeutics and Lilly to Collaborate on Novel Regulatory Genome Targets for Obesity and Related Metabolic Conditions with Proprietary RNA Tech.

HAYA Therapeutics Announces Collaboration with Lilly to Discover Novel Regulatory Genome Targets for Obesity and Related Metabolic Conditions Using Proprietary RNA Platform

Eli Lilly's weight loss treatment Zepbound might be a blockbuster in the making, but it wasn't without its challenges. The company faced criticism for high prices, supply blockages and the rise of counterfeits. It has now addressed all these concerns. Zepbound's price cuts can make at least some customers happy, its latest packaging allows for bigger supplies, and the online portal can reduce the use of non-prescription medication.

Eli Lilly: Zepbound Price Cuts Have Multiple Positives, Limited Downside

Eli Lilly and Egypt's EVA Pharma have entered into an agreement to license Lilly's rheumatoid arthritis drug in 49 countries in Africa, the companies said on Wednesday.

Eli Lilly to license arthritis drug to Egypt's EVA Pharma

Lilly will license certain baricitinib manufacturing know-how to enable EVA Pharma to manufacture and supply treatment for various immunological diseases across 49 low- to middle-income countries in Africa INDIANAPOLIS and CAIRO , Sept. 4, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and  EVA Pharma  announced today that the companies have entered into an agreement to expand access to baricitinib to an estimated 20,000 people in 49 low- to middle-income countries in Africa by 2030.

Lilly and EVA Pharma collaborate to expand access to baricitinib in low- to middle-income countries

Hims & Hers Health

Capitalizing on the popularity of weight-loss drugs like Wegovy and Zepbound, Hims & Hers Health (NYSE:HIMS) has exploited a loophole in Food & Drug Administration regulations to bring to market similar drugs without having to undergo the rigors of clinical testing the pharmaceutical giants are required to pursue.

Has Eli Lilly Destroyed Hims & Hers Upside?

BioAge Labs, a biotech startup collaborating with Eli Lilly for its obesity therapy, said on Tuesday it had filed for an initial public offering in the United States.

Eli Lilly partner BioAge files for US IPO

Lockheed Martin

3 Big Winners from the Q2 Earnings Season: LLY, LMT, META

While Novo is struggling to keep up with demand for its obesity drugs, U.S. rival Eli Lilly sees supply restraints easing.

News for Eli Lilly Stock (LLY)